Catechol estrogens such as 2-OH estrone are interesting estrogen metabolitesformed in several human tissuesand excreted in urine.We developed and thoroughlyvalidateda radioimmunoassayfor urinary 2-OH estrone that has several advantages over published AlAs. Because we developed a relatively specific antiserum, we did not include a preliminarychromatographicstep to eliminate cross-reacting urinary steroids. We hydrolyzed urinary steroid conjugates with -glucuronidase from Helix properties, including inhibition of catechol-O-methyltransferase (6, 7) and tyrosine hydroxylase (8). They may influence the secretion of luteinizing hormone (9), prolactin (10), and prostaglandins (11). The 2-OH derivatives have less affinity than the 4-OH derivatives and estradiol-17 for uterine estrogen receptors (12).
compared the effects of acid and enzyme hydrolysis on recoveries of 2-OH estrone. We generated a relatively specific antiserum and thus did not include a preliminary chromatographic step to remove cross-reacting steroids. We determined the ability of this RIA to measure 2-OH estrone concentrations independently of the sample volume (by relation to creatinine clearance) and established normal ranges of values in 11 regularly menstruating women. We used the RIA to measure urinary 2-OH estrone in 33 women shortly after diagnosis of breast cancer and in 14 age-matched controls.
Materials and Methods

Subjects
To investigate the concentrations of 2-OH estrone during the menstrual cycle we selected 11 female control subjects, ages 21 to 40 years. They were in good health, had regular menstrual cycles (mean 29 days, SD 3 days), were nonsmokers, and were not taking oral contraceptives or other drugs. After an overnight fast they collected, during one menstrual cycle, an earlymorning urine sample every secondmorning in 20-mL bottles that contained 600 mg of ascorbicacid. The start of each cycle was defined as 1 day after the onset of bleeding. An early-morning saliva sample for progesterone measurement was also provided by each volunteer, beginning on day 7 and concluding on day 21 of the cycle. Urine and saliva samples were stored at -20#{176}C.
Ovulation was confirmed by enzyme immunoassay of salivary progesterone (19, 20) .
Another group of control subjects were 14 postmenopausal women, ages 47 to 93 years, in goodhealth, nonsmokers, and not taking medication. They collected one early-morning urine sample, as described above, after an overnight fast. We also studied 33 women, ages 51 to 74 years, who were diagnosed with carcinoma of breast; they collected urine samples after an overnight fast, as soon as feasible after diagnosis and before therapy commenced.
Aeagents
Tetrahydrofuran was obtained from Reidel-de Haen (Seeize, Germany); f3-glucuronidase (from Helix pomatia), potassium iodide, and sodium bisulfite from Sigma (Poole, Dorset, UK); glass hydrolysis tubes from Hach (Loveland, CO); and precoated silica gel 60 F HPLC system (Milton Roy, Stone, Staffordshire, UK) used a CM400 multiple-solvent delivery system, SM400 We dissolved sodium acetate trthydrate (6 mg) and carboxymethoxylamine hemihydrochioride (6 mg) in 1 drop of H2O followed by 100 LL of methanol and added this to 10 mg of 2-OH estrone previously dissolved in 0.5 mL of methanol. We allowed the mixture to stand at room temperature (18#{176}C) in a sealed glass container under nitrogen. The progress of the reaction was monitored by thin-layer chromatography on sifica gel 60 F5 with use of chioroform/methanol/acetic acid (4/1/0.2 by vol) as the mobile phase. After 24 h, we added 5 mL of H2O and extracted the reaction mixture with two 10-mL portions of ethyl acetate. The extract was dried by rotary evaporation, and the precipitate was redissolved in a mixture of deuterated chloro- The titer of the antiserum after the last immunization was 1:12 000 (in 100 L per test).
2-OH estrone-17-CMO
All dilutions of the antiserum were performed in assay buffer. 
RIA of 2-OH Estrone
Optimization studies with the assay included the characterization and selection of suitable buffers and volumes 
2-OH
Results
Analytical Variables
Standard curve and precision profile. The standard curve (Fig. 1) represents the mean from 19 assays performed during 6 months, with triplicate determination of standards. The detection limit, defined as the concentration of 2-OH estrone required to give a B/B0 of 2 SD below the mean counts per minute observed in the absence of cold hormone, ranged between <10 and 24 pg/test (100 to 240 ng'L) over 19 assay runs. The EDso was 37 pg/test (370 ng/L), which is about twice as much as the detection limit of the assay. This is due to the relatively high affinity of the antiserum, which resulted in a standard curve with a steep slope. The precision profile, which represents the within-assay CV for three samples over the range of the standard curve, is also shown (Fig. 1) . Table 1 shows the inter-and intraassay variations for a low, medium, and above-normal urinary concentration of 2-OH estrone after enzyme hydrolysis of replicate samples on each assay.
Specificity. The specificity of the antiserum used for 2-OH estrone was assessedfor a range of structurally We established the ability of the assay to accurately measure 2-OH estrone added to urine samples that contained a range of endogenous2-OH estrone concentrations. Extraction efficiency, after either acid or enzyme hydrolysis, was assessed by adding two different concentrations of 2-OH estrone to two urine samples from different subjects ( Table 3) . Total 2-OH estrone was measured, and the recovery of added steroid was calculated after subtracting the endogenoussteroid concentration. Overall mean recoveries of added standard after acid or enzyme hydrolysis were 49.6% and 73.8%, respectively. Consequently, we used enzyme hydrolysis to release 2-OH estrone from its conjugates in urine.
Independence of volume.
We assessed the ability of the assay to measure 2-OH estrone independently of the volume of sample after enzyme hydrolysis. After initial dilutions of hydrolysates to bring them within the range of the standard curve, we assayed a range of sample volumes between 50 and 120 L. The assay measured The following steroids were also tested and gave cross-reactlvitles of <0.025%: androstenedlone, cholesterol, corticosterone,progesterone, testosterone, and tamoxifen. (Fig. 2) . Independence of volume was also demonstrated after acid hydrolysis (data not shown). Stability of 2-OH estrone in urine. Aliquots (2 mL) of first-void urine samples from two of the premenopausal controls were stored at various temperatures with and without ascorbic acid (30 giL): -70, -20, and 4#{176}C. 2-OH estrone was measured at weekly intervals for 6 weeks after tetrahydrofuran extraction and enzyme hydrolysis. The concentration of 2-OH estrone did not change in either set of urine samples after 41 days under any of the storage conditions. However, 2-OH estrone concentrations in samples stored in the absence of ascorbic acid were between 80.6% and 74.4% of the values in the same samples stored in the presence of ascorbic acid. We found that the combination of ascorbic acid and EDTA in the assay buffer after acid hydrolysis displaced the antiserum (B/BO, 70.5% ± 2.1%) unless diluted fivefold (100% B/B0). This corresponds with the dilutions necessary to bring urinary 2-OH estrone concentrations within the range of the standard curve. progesterone in daily saliva samples taken 7 days after commencement of menses. It was possible to give approximate time of ovulation from salivary progesterone proliles and menstrual histories (20) . The concentrations of 2-OH estrone fluctuated during the cycles and 21.5 showed a major preovulatory peak at midcycle (Fig. 3) .
Clinical Samples
Variations during
34.5
Mean (±SD) concentrations in the luteal phase were (Fig. 4) . 
DiscussIon
This RIA of 2-OH estrone in urine has several advantages over published RIAs (17, 18 Table  3) . This difference persisted in urine samples assayed with and without the addition of 2-OH estrone. We assessed the recovery of controls with added 2-OH estrone but not with added 2-OH estrone glucuronide because we were unable to find a source to supply the latter steroid. The relatively high specificity of the antiserum precluded recovery studies with structurally related steroids such as estrone glucuronide. We therefore recommended using enzyme hydrolysis instead of acid hydrolysis.
We developed a relatively specific antiserum for 2-OH estrone and characterized its cross-reactivity against 14 steroids, including several that are structurally similAr to 2-OH estrone. Only two, 2-OH estradiol and 2-OH estriol, displayed significant cross-reactivities (17.4% and 14.4%, respectively; Table 2 ). Concentrations of these two catechol estrogens are relatively low, even in pregnant women (17) . Although it would have been useful to compare values with and without chromatography, we did not include in this RIA, because of the relatively high specificity of this antiserum for 2-OH estrone, a preliminary chromatographic purification step that is used in RIAs with less-specific antisera (17). (17, 18) . We demonstrated that this RLA measures 2-OH estrone in urine independently of the volume assayed, in the range 50 to 120 pL.
The detection
We confirmed previous observations that ascorbic acid stabilizes 2-OH estrone, but we also found that, in combination with EDTA in the immunoassay buffer, it could interfere with the RIA unless diluted fivefold.
We established ranges of normal values in 11 regularly menstruating women. Concentrations of 2-OH estrogens but not of 2-OH estrone alone were measured during the menstrual cycle in a previous study (25) . We showed that the concentrations of 2-OH estrone fluctuate during the menstrual cyde in these women, in whom ovulation was confirmed by midcycle increases in salivary progesterone. The changes in concentrations were similar to those reported for total 2-OH estrogens (25) . (Fig. 4) . Increased 2-hydroxylation of estrogens was previously reported in serum of 15 women with breast cancer, compared with 10 controls (26). It is difficult, however, to compare our results because absolute values for 2-OH estrone were not given in those studies. Others found increased 2-hydroxylation of estrone in breast tumors in vitro (27) .
Because of the overlap between values for controls and breast cancer patients, 2-OH estrone measurements are probably not useful for screening or diagnosi of breast carcinoma. To determine whether urinary 2-t)H estrone measurements are useful for monitoring the course of breast cancer or the development of relapse, larger numbers of patients should be investigated with a thoroughly validated immunoassay such as the one described here.
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